A Phase 2 interventional study of Conjugated meningococcal ACWY-TT (vaccine) and DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 17 sites in 2 countries. Open to participants aged 12 Months to 60 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-08.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Meningococcal Infections by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · GlaxoSmithKline.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 43rd largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2005, is one of 25 in phase 2, and was the 7th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →None of the 71 studies in Meningococcal Infections by GlaxoSmithKline is open now. The open studies under Meningococcal Infections, anywhere →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 12 Months to 60 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 26 · Phase 3 34 · Phase 4 6
First in 2002; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 461 is close to the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 613 across the 67 interventional studies, 119 across the 4 observational. Of the 70 that completed or were terminated, 60 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one dose of four different formulations of the MenACWY conjugate vaccine when given to healthy children aged 12-14 months and 3-5 years. The selection of the best formulation will be based on data obtained up to one month after the vaccine dose.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
The study will enrol subjects of 12 to 14 months of age and subjects of 3 to 5 years of age. 3 formulations of GSK's MenACWY conjugate vaccine will be administered in a double-blind manner, while the 4th one will be single-blinded. Administration of the candidate vaccine or the active controls (MenC-CRM197 or Mencevax™ ACWY) will be done in an open manner. The study will be conducted in two stages: The primary vaccination phase (Study Stage 1) of the study will include all subjects; the second (booster/persistence) phase of the study (Study Stage 2) will include subjects in the active control groups and in the group which was primed with the selected MenACWY formulation.
The study will be conducted in a double-blind manner for groups receiving formulations A, B, C and in single blind manner with respect to the group receiving formulation D. The control vaccines will be administered in an open manner with respect to the investigational vaccination regimens.
Each group will have one blood sample prior to and one blood sample one month after the first vaccine dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
For subjects aged 12-14 months at enrolment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) · Biological: Mencevax™ACWY
Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer's Meningitec™ conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) · Biological: Meningitec™ · Biological: Mencevax™ACWY
Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib) · Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).
Biological: Mencevax™ACWY
Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
Biological: Conjugated meningococcal ACWY-TT (vaccine) · Biological: Mencevax™ACWY
Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
Biological: Meningitec™ · Biological: Mencevax™ACWY
Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.
Biological: Conjugated meningococcal ACWY-TT (vaccine)
Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, did not receive any booster vaccination.
Biological: Meningitec™
One intramuscular dose during the primary vaccination
One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
Drug page: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineStudies of Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineDiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
Number of Subjects With an Immune Response to Different Meningococcal Serogroups
A responder to serum bactericidal assay meningococcal serogroups A, C, W and Y, using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) was defined as follows: -for initially seronegative subjects (antibody titers \< 1:8 for rSBA-Men), a subject achieving a post-vaccination rSBA-Men antibody titer of ≥ 1:32; - for initially seropositive subjects (antibody titers ≥ 1:8 for rSBA-Men), a subject having a ≥ 4-fold increase in rSBA-Men antibody titer from pre to post vaccination.
Time frame: One month after the first vaccine dose (Month 1)
Number of Seroprotected Subjects Against Different Meningococcal Serogroups
A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.
Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Number of Seropositive Subjects for Different Anti-meningococcal Serogroups
A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.
Time frame: Prior to (Month 0) and one month after (Month 1) after the first vaccine dose
Antibody Titers Against Different Meningococcal Serogroups
Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).
Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides
A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides
A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Antibody Concentrations Against Different Meningococcal Polysaccharides
The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).
Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Number of Seropositive Subjects for Anti-tetanus (Anti-T)
A seropositive subject for anti-tetanus was defined as having antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units per milliliter (IU/mL). Antibody titers were determined by enzyme-linked immunosorbent assay (ELISA).
Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Antibody Concentrations Against Tetanus (Anti-T)
Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) method, presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).
Time frame: Prior to (Month 0) and one month after (Month 1) the first vaccine dose
Number of Toddlers With Any Solicited Local Symptoms
The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose
Number of Children With Any Solicited Local Symptoms
The children subgroup received one dose of the meningococcal vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose
Number of Toddlers With Any Solicited General Symptoms
The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited general symptoms included drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.
Time frame: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose
Number of Children With Any Solicited General Symptoms
The children subgroup received one primary meningococcal vaccine dose. Assessed solicited general symptoms included drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.
Time frame: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose
Number of Seroprotected Subjects Against Different Meningococcal Serogroups
A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.
Time frame: At one month (M1) and 12 months (M12) post-primary vaccination
Number of Seropositive Subjects for Different Anti-meningococcal Serogroups
A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.
Time frame: At one month (M1) and 12 months (M12) post-primary vaccination
Antibody Titers Against Different Meningococcal Serogroups
Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).
Time frame: At one month (M1) and 12 months (M12) post-primary vaccination
Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides
A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Time frame: At one month (M1) and 12 months (M12) post-primary vaccination
Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides
A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Time frame: At one month (M1) and 12 months (M12) post primary vaccination
Antibody Concentrations Against Different Meningococcal Polysaccharides
The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).
Time frame: At one month (M1) and 12 months (M12) post-primary vaccination
Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups
A seropositive subject for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY was defined as a vaccinated subject with antibody titers greater than or equal to (≥) 1:128, while for a seroprotected subject, titers were ≥1:8.
Time frame: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination
Antibody Titers Against Different Meningococcal Serogroups
Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).
Time frame: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination
Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides
A seropositive subject for anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY was defined as a vaccinated subject with antibody concentrations greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL), while for a seroprotected subject, antibody concentrations were ≥ 2.0 μg/mL.
Time frame: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination
Antibody Concentrations Against Different Meningococcal Polysaccharides
The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).
Time frame: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 8-day (Days 0-7) post-vaccination period following booster dose
Number of Subjects With Any Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, fever \[defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.
Time frame: During the 8-day (Days 0-7) post-vaccination period following booster dose
Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 31 days (Days 0-30) after the primary meningococcal vaccination
Number of Subjects With Any Unsolicited AEs During the Primary Vaccination
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 31 days (Days 0-30) post-vaccination with diphteria, tetanus and acellular pertusis-containing vaccine, during the primary vaccination
Number of Subjects With Any Unsolicited AEs
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 31 days (Days 0-30) after the booster vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the primary vaccination study (from Month 0 up to Month 2)
Number of Subjects With SAEs
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Since the last study contact in the primary study up to the end of the booster study (from Month 2 up to Month 13)
| Milestone | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 39 | 41 | 41 | 40 | 40 | 54 | 50 | 52 | 52 | 52 | 0 | 0 | 0 | 0 |
| Completed | 38 | 40 | 37 | 39 | 37 | 52 | 50 | 49 | 52 | 51 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 4 | 1 | 3 | 2 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Migrated from study area | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 32 | 45 | 43 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 30 | 45 | 43 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
A responder to serum bactericidal assay meningococcal serogroups A, C, W and Y, using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) was defined as follows: -for initially seronegative subjects (antibody titers \< 1:8 for rSBA-Men), a subject achieving a post-vaccination rSBA-Men antibody titer of ≥ 1:32; - for initially seropositive subjects (antibody titers ≥ 1:8 for rSBA-Men), a subject having a ≥ 4-fold increase in rSBA-Men antibody titer from pre to post vaccination.
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| rSBA-MenA | 30 | 32 | 26 | 27 | 6 | 41 | 38 | 41 | 42 | 36 |
| rSBA-MenC | 30 | 32 | 26 | 33 | 30 | 45 | 44 | 44 | 46 | 34 |
| rSBA-MenW-135 | 34 | 36 | 27 | 35 | 3 | 46 | 44 | 46 | 48 | 36 |
| rSBA-MenY | 33 | 34 | 26 | 34 | 3 | 46 | 47 | 45 | 47 | 34 |
A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| rSBA-MenA, Month 0 | 23 | 22 | 19 | 21 | 20 | 41 | 42 | 40 | 47 | 39 |
| rSBA-MenA, Month 1 | 36 | 38 | 30 | 34 | 23 | 50 | 47 | 48 | 50 | 43 |
| rSBA-MenC, Month 0 | 5 | 2 | 2 | 5 | 3 | 16 | 8 | 17 | 12 | 14 |
| rSBA-MenC, Month 1 | 36 | 38 | 28 | 35 | 34 | 50 | 47 | 47 | 49 | 43 |
| rSBA-MenW-135, Month 0 | 17 | 19 | 12 | 13 | 15 | 34 | 24 | 25 | 36 | 27 |
| rSBA-MenW-135, Month 1 | 35 | 38 | 30 | 35 | 15 | 50 | 48 | 48 | 50 | 44 |
| rSBA-MenY, Month 0 | 23 | 17 | 16 | 19 | 22 | 37 | 42 | 39 | 42 | 36 |
| rSBA-MenY, Month 1 | 35 | 38 | 29 | 35 | 25 | 51 | 48 | 48 | 50 | 44 |
A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| rSBA-MenA, Month 0 | 19 | 19 | 13 | 19 | 17 | 41 | 39 | 40 | 46 | 37 |
| rSBA-MenA, Month 1 | 36 | 38 | 29 | 34 | 20 | 49 | 47 | 48 | 50 | 43 |
| rSBA-MenC, Month 0 | 3 | 0 | 0 | 3 | 1 | 9 | 4 | 5 | 7 | 5 |
| rSBA-MenC, Month 1 | 35 | 34 | 26 | 31 | 27 | 49 | 46 | 45 | 48 | 39 |
| rSBA-MenW-135, Month 0 | 8 | 9 | 4 | 4 | 8 | 19 | 11 | 9 | 15 | 12 |
| rSBA-MenW-135, Month 1 | 35 | 38 | 29 | 35 | 9 | 50 | 48 | 48 | 49 | 42 |
| rSBA-MenY, Month 0 | 17 | 11 | 9 | 12 | 17 | 29 | 37 | 32 | 33 | 30 |
| rSBA-MenY, Month 1 | 35 | 37 | 29 | 34 | 18 | 51 | 48 | 48 | 50 | 43 |
Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).
| Titers | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| rSBA-MenA, Month 0 | 84.2 (39.3 to 180.1) | 77.3 (32.9 to 181.6) | 68.4 (30.1 to 155.3) | 76 (33.8 to 170.8) | 69.1 (28.1 to 169.9) | 359.7 (212 to 610.4) | 367.2 (222.1 to 607) | 375.9 (227.4 to 621.2) | 465.2 (307.2 to 704.4) | 427.4 (280.3 to 651.7) |
| rSBA-MenA, Month 1 | 6648 (4787.3 to 9231.9) | 5406.8 (3961.5 to 7379.4) | 6225.2 (3510.2 to 11040.2) | 3928.6 (2851.5 to 5412.4) | 125.9 (53.1 to 298.3) | 7469.5 (5468.8 to 10202.1) | 7569.7 (6044 to 9480.6) | 13668.3 (11274.3 to 16570.6) | 4878 (4002.5 to 5944.9) | 4556.8 (3598 to 5771.1) |
| rSBA-MenC, Month 0 | 6.9 (4.1 to 11.5) | 4.5 (3.8 to 5.2) | 4.6 (3.8 to 5.7) | 6.6 (4.2 to 10.2) | 5.3 (3.8 to 7.3) | 12.5 (7.6 to 20.5) | 7.4 (4.7 to 11.6) | 11.8 (7.5 to 18.5) | 8.9 (5.7 to 14.1) | 11.9 (7 to 20.2) |
| rSBA-MenC, Month 1 | 656.4 (483 to 892) | 495.7 (334.6 to 734.4) | 477.2 (245.1 to 929.4) | 464.3 (324.4 to 664.5) | 404.5 (222.5 to 735.4) | 967.6 (672 to 1393.3) | 1115 (746.4 to 1665.7) | 1738.8 (1159.7 to 2607) | 1197.6 (765 to 1874.7) | 378.3 (257.2 to 556.5) |
| rSBA-MenW-135, Month 0 | 19.8 (10.7 to 36.9) | 21.1 (11.5 to 38.6) | 14.5 (7.7 to 27.3) | 12.1 (7.1 to 20.6) | 18 (9.7 to 33.6) | 45.8 (27.9 to 75.2) | 22.3 (12.7 to 39) | 23.7 (14.2 to 39.7) | 44.6 (28.1 to 71) | 31.5 (18 to 55) |
| rSBA-MenW-135, Month 1 | 2781.4 (1647 to 4697.2) | 3447.5 (2484.8 to 4783.3) | 2545 (1522.2 to 4254.9) | 3260.8 (2342.1 to 4539.8) | 21.7 (10.5 to 44.9) | 4317.4 (3114.8 to 5984.3) | 3856.5 (3153.4 to 4716.4) | 5262.1 (4417.8 to 6267.7) | 4556.1 (3576.6 to 5803.7) | 912.7 (659.1 to 1264.1) |
| rSBA-MenY, Month 0 | 57.7 (27.5 to 121.3) | 24.4 (12 to 49.7) | 32.4 (14.3 to 73) | 32.9 (15.9 to 68.3) | 52.8 (25.5 to 109.5) | 98.7 (54.9 to 177.5) | 181.9 (112.1 to 295.3) | 146.8 (86.2 to 250.1) | 140.6 (82.8 to 238.9) | 123.6 (73.3 to 208.6) |
| rSBA-MenY, Month 1 | 2599.9 (1531.8 to 4412.7) | 2150.9 (1486.2 to 3112.9) | 1920.9 (1014.2 to 3638.2) | 3544.7 (2480.2 to 5065.9) | 75.6 (38.1 to 150.1) | 5249.1 (4107.9 to 6707.4) | 5150.5 (4149.8 to 6392.6) | 5896.3 (4686.4 to 7418.5) | 7548.4 (6116.1 to 9316.2) | 1527.3 (1110.8 to 2099.9) |
A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-PSA, Month 0 | 1 | 2 | 0 | 1 | 0 | 10 | 4 | 6 | 9 | 10 |
| Anti-PSA, Month 1 | 35 | 36 | 30 | 34 | 2 | 48 | 45 | 48 | 48 | 44 |
| Anti-PSC, Month 0 | 1 | 1 | 0 | 1 | 1 | 3 | 4 | 1 | 1 | 2 |
| Anti-PSC, Month 1 | 33 | 38 | 30 | 35 | 34 | 49 | 45 | 48 | 48 | 44 |
| Anti-PSW-135, Month 0 | 1 | 0 | 1 | 1 | 0 | 1 | 4 | 2 | 0 | 1 |
| Anti-PSW-135, Month 1 | 34 | 36 | 30 | 35 | 0 | 48 | 45 | 48 | 48 | 44 |
| Anti-PSY, Month 0 | 2 | 0 | 2 | 1 | 1 | 2 | 4 | 2 | 1 | 1 |
| Anti-PSY, Month 1 | 34 | 37 | 30 | 34 | 2 | 49 | 45 | 46 | 48 | 44 |
A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-PSA, Month 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 5 |
| Anti-PSA, Month 1 | 35 | 35 | 30 | 25 | 0 | 48 | 44 | 47 | 34 | 40 |
| Anti-PSC, Month 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 2 |
| Anti-PSC, Month 1 | 33 | 37 | 29 | 34 | 33 | 44 | 45 | 45 | 47 | 44 |
| Anti-PSW-135, Month 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Anti-PSW-135, Month 1 | 33 | 27 | 23 | 32 | 0 | 41 | 31 | 41 | 39 | 39 |
| Anti-PSY, Month 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 |
| Anti-PSY, Month 1 | 34 | 34 | 27 | 33 | 0 | 46 | 40 | 39 | 47 | 42 |
The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).
| μg/mL | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-PSA, Month 0 | 0.16 (0.14 to 0.18) | 0.16 (0.14 to 0.19) | 0.15 (0.15 to 0.15) | 0.16 (0.14 to 0.17) | 0.15 (0.15 to 0.15) | 0.2 (0.17 to 0.25) | 0.17 (0.15 to 0.2) | 0.17 (0.15 to 0.19) | 0.21 (0.17 to 0.26) | 0.25 (0.18 to 0.35) |
| Anti-PSA, Month 1 | 30.65 (19.83 to 47.38) | 22.09 (16.35 to 29.84) | 34.68 (21.7 to 55.42) | 4.03 (2.72 to 5.98) | 0.17 (0.14 to 0.2) | 20.01 (14.53 to 27.56) | 12.62 (8.74 to 18.22) | 24.69 (19.14 to 31.85) | 3.63 (2.62 to 5.04) | 13.79 (9.04 to 21.02) |
| Anti-PSC, Month 0 | 0.16 (0.14 to 0.17) | 0.16 (0.14 to 0.17) | 0.15 (0.15 to 0.15) | 0.15 (0.15 to 0.16) | 0.16 (0.14 to 0.17) | 0.18 (0.15 to 0.22) | 0.18 (0.15 to 0.23) | 0.16 (0.14 to 0.17) | 0.15 (0.15 to 0.16) | 0.18 (0.14 to 0.22) |
| Anti-PSC, Month 1 | 10.67 (7.47 to 15.23) | 11.23 (8.75 to 14.4) | 12.91 (8.83 to 18.88) | 10.74 (8.43 to 13.68) | 11.99 (9.26 to 15.53) | 6.33 (4.81 to 8.34) | 7.76 (5.76 to 10.44) | 7.71 (6.05 to 9.83) | 7.78 (5.83 to 10.38) | 14.44 (11.32 to 18.42) |
| Anti-PSW-135, Month 0 | 0.15 (0.15 to 0.16) | 0.15 (0.15 to 0.15) | 0.16 (0.14 to 0.17) | 0.15 (0.15 to 0.16) | 0.15 (0.15 to 0.15) | 0.15 (0.15 to 0.16) | 0.17 (0.15 to 0.2) | 0.16 (0.15 to 0.17) | 0.15 (0.15 to 0.15) | 0.16 (0.14 to 0.17) |
| Anti-PSW-135, Month 1 | 7.52 (4.97 to 11.36) | 3.12 (2.3 to 4.22) | 3.62 (2.31 to 5.68) | 7.09 (5.19 to 9.7) | 0.15 (0.15 to 0.15) | 4.76 (3.4 to 6.66) | 3.2 (2.33 to 4.39) | 3.85 (2.85 to 5.21) | 4.99 (3.7 to 6.73) | 7.93 (5.39 to 11.66) |
| Anti-PSY, Month 0 | 0.16 (0.14 to 0.18) | 0.15 (0.15 to 0.15) | 0.16 (0.15 to 0.17) | 0.16 (0.14 to 0.2) | 0.15 (0.15 to 0.16) | 0.16 (0.14 to 0.18) | 0.19 (0.15 to 0.24) | 0.16 (0.15 to 0.17) | 0.15 (0.15 to 0.16) | 0.15 (0.15 to 0.16) |
| Anti-PSY, Month 1 | 10.86 (7.41 to 15.92) | 6.71 (5.12 to 8.8) | 6.01 (4 to 9.03) | 13.38 (9.48 to 18.89) | 0.16 (0.15 to 0.17) | 9.41 (6.66 to 13.31) | 6.59 (4.7 to 9.25) | 5.75 (4.23 to 7.81) | 11.7 (8.39 to 16.32) | 18.96 (13.68 to 26.29) |
A seropositive subject for anti-tetanus was defined as having antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units per milliliter (IU/mL). Antibody titers were determined by enzyme-linked immunosorbent assay (ELISA).
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-T, Month 0 | 34 | 36 | 30 | 32 | 33 | 49 | 47 | 46 | 48 | 43 |
| Anti-T, Month 1 | 36 | 37 | 30 | 35 | 34 | 48 | 47 | 48 | 50 | 43 |
Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) method, presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).
| IU/mL | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-T, Month 0 | 1.007 (0.671 to 1.51) | 1.159 (0.814 to 1.65) | 1.203 (0.871 to 1.662) | 1.293 (0.826 to 2.023) | 0.792 (0.578 to 1.084) | 1.426 (0.94 to 2.164) | 1.312 (0.935 to 1.841) | 1.232 (0.849 to 1.788) | 1.18 (0.823 to 1.694) | 1.083 (0.742 to 1.58) |
| Anti-T, Month 1 | 7.559 (5.04 to 11.335) | 5.353 (3.832 to 7.477) | 8.094 (4.855 to 13.492) | 7.675 (4.783 to 12.315) | 0.696 (0.52 to 0.932) | 17.284 (11.812 to 25.292) | 15.823 (11.728 to 21.348) | 19.369 (13.226 to 28.363) | 15.957 (11.767 to 21.639) | 1.231 (0.833 to 1.82) |
The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group |
|---|---|---|---|---|---|
| Pain, Dose 1 | 4 | 8 | 3 | 6 | 4 |
| Redness, Dose 1 | 9 | 12 | 10 | 9 | 11 |
| Swelling, Dose 1 | 1 | 6 | 7 | 6 | 4 |
| Pain, Dose 2 | 3 | 10 | 6 | 7 | 6 |
| Redness, Dose 2 | 7 | 13 | 9 | 8 | 7 |
| Swelling, Dose 2 | 3 | 7 | 9 | 7 | 3 |
The children subgroup received one dose of the meningococcal vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
| Participants | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|
| Pain | 10 | 11 | 9 | 11 | 13 |
| Redness | 9 | 11 | 10 | 9 | 7 |
| Swelling | 7 | 9 | 8 | 10 | 4 |
The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited general symptoms included drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group |
|---|---|---|---|---|---|
| Drowsiness, Dose 1 | 1 | 5 | 4 | 4 | 5 |
| Fever (Axillary), Dose 1 | 5 | 8 | 8 | 3 | 5 |
| Irritability, Dose 1 | 4 | 9 | 6 | 5 | 5 |
| Loss of appetite, Dose 1 | 1 | 6 | 5 | 3 | 6 |
| Drowsiness, Dose 2 | 2 | 2 | 3 | 7 | 3 |
| Fever (Axillary), Dose 2 | 4 | 5 | 5 | 5 | 8 |
| Irritability, Dose 2 | 6 | 7 | 3 | 9 | 5 |
| Loss of appetite, Dose 2 | 4 | 3 | 2 | 6 | 2 |
The children subgroup received one primary meningococcal vaccine dose. Assessed solicited general symptoms included drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.
| Participants | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|
| Drowsiness | 4 | 2 | 0 | 5 | 4 |
| Fever (Axillary) | 4 | 4 | 3 | 3 | 3 |
| Irritability | 2 | 4 | 2 | 4 | 7 |
| Loss of appetite | 2 | 3 | 2 | 6 | 3 |
A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8.
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|
| rSBA-MenA, Month 1 | 31 | 18 | 43 | 36 |
| rSBA-MenC, Month 1 | 31 | 29 | 43 | 36 |
| rSBA-MenW-135, Month 1 | 30 | 11 | 43 | 37 |
| rSBA-MenY, Month 1 | 30 | 20 | 44 | 37 |
| rSBA-MenA, Month 12 | 23 | 20 | 39 | 33 |
| rSBA-MenC, Month 12 | 29 | 25 | 40 | 22 |
| rSBA-MenW-135, Month 12 | 30 | 11 | 41 | 31 |
| rSBA-MenY, Month 12 | 31 | 23 | 41 | 36 |
A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128.
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|
| rSBA-MenA, Month 1 | 31 | 14 | 42 | 36 |
| rSBA-MenC, Month 1 | 31 | 23 | 42 | 34 |
| rSBA-MenW-135, Month 1 | 30 | 6 | 43 | 35 |
| rSBA-MenY, Month 1 | 30 | 13 | 44 | 36 |
| rSBA-MenA, Month 12 | 23 | 19 | 39 | 32 |
| rSBA-MenC, Month 12 | 13 | 15 | 27 | 10 |
| rSBA-MenW-135, Month 12 | 27 | 6 | 41 | 27 |
| rSBA-MenY, Month 12 | 30 | 17 | 40 | 32 |
Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).
| Titers | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|
| rSBA-MenA, Month 1 | 6577.8 (4606.7 to 9392.4) | 84.9 (32.4 to 222.8) | 6565.3 (4616.3 to 9337.2) | 4649.5 (3572.8 to 6050.8) |
| rSBA-MenC, Month 1 | 660.4 (484.4 to 900.3) | 440.2 (227.1 to 853.1) | 893.6 (600.3 to 1330.3) | 416.2 (270.5 to 640.5) |
| rSBA-MenW-135, Month 1 | 2523.5 (1433.1 to 4443.7) | 17.2 (7.9 to 37.8) | 3893.6 (2671.2 to 5675.6) | 1004.4 (690.4 to 1461.2) |
| rSBA-MenY, Month 1 | 2483.9 (1363.8 to 4524.1) | 57.7 (27.1 to 123.2) | 4808.5 (3653 to 6329.6) | 1641.1 (1131.2 to 2380.9) |
| rSBA-MenA, Month 12 | 2369.1 (1642 to 3418.2) | 179.3 (76.1 to 422.9) | 2356.7 (1786.7 to 3108.4) | 1134.3 (767.8 to 1675.5) |
| rSBA-MenC, Month 12 | 110.2 (60.6 to 200.7) | 122 (59 to 252.2) | 172.5 (117.7 to 252.9) | 41.7 (22 to 79.2) |
| rSBA-MenW-135, Month 12 | 541.8 (305.5 to 961) | 18.9 (8.4 to 42.9) | 1322.2 (978.3 to 1786.8) | 181.7 (104.6 to 315.8) |
| rSBA-MenY, Month 12 | 740.3 (493.4 to 1110.9) | 110.6 (51.6 to 237.1) | 1400.8 (1008.8 to 1945.1) | 347.2 (228.2 to 528.5) |
A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|
| Anti-PSA, Month 1 | 30 | 1 | 41 | 37 |
| Anti-PSC, Month 1 | 28 | 30 | 42 | 37 |
| Anti-PSW-135, Month 1 | 29 | 0 | 41 | 37 |
| Anti-PSY, Month 1 | 29 | 2 | 42 | 37 |
| Anti-PSA, Month 12 | 22 | 2 | 34 | 34 |
| Anti-PSC, Month 12 | 13 | 18 | 18 | 36 |
| Anti-PSW-135, Month 12 | 25 | 3 | 34 | 32 |
| Anti-PSY, Month 12 | 26 | 3 | 34 | 35 |
A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|
| Anti-PSA, Month 1 | 30 | 0 | 41 | 33 |
| Anti-PSC, Month 1 | 28 | 29 | 37 | 37 |
| Anti-PSW-135, Month 1 | 28 | 0 | 34 | 32 |
| Anti-PSY, Month 1 | 29 | 0 | 39 | 35 |
| Anti-PSA, Month 12 | 10 | 0 | 12 | 22 |
| Anti-PSC, Month 12 | 2 | 4 | 0 | 24 |
| Anti-PSW-135, Month 12 | 6 | 2 | 10 | 23 |
| Anti-PSY, Month 12 | 15 | 1 | 19 | 30 |
The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).
| µg/mL | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|
| Anti-PSA, Month 1 | 32.72 (20.12 to 53.22) | 0.17 (0.14 to 0.2) | 18.29 (12.86 to 26.01) | 13 (8.19 to 20.63) |
| Anti-PSC, Month 1 | 11.25 (7.48 to 16.93) | 12.43 (9.28 to 16.65) | 5.64 (4.21 to 7.57) | 14.5 (11.01 to 19.1) |
| Anti-PSW-135, Month 1 | 6.65 (4.29 to 10.3) | 0.15 (0.15 to 0.15) | 4.23 (2.94 to 6.09) | 8.17 (5.19 to 12.86) |
| Anti-PSY, Month 1 | 10.37 (6.74 to 15.94) | 0.16 (0.15 to 0.17) | 8.07 (5.79 to 11.24) | 18.12 (12.41 to 26.46) |
| Anti-PSA, Month 12 | 1.25 (0.68 to 2.3) | 0.17 (0.14 to 0.21) | 1.32 (0.9 to 1.95) | 4.43 (2.55 to 7.7) |
| Anti-PSC, Month 12 | 0.39 (0.23 to 0.66) | 0.54 (0.34 to 0.86) | 0.28 (0.22 to 0.36) | 2.9 (1.94 to 4.35) |
| Anti-PSW-135, Month 12 | 1.36 (1.06 to 1.74) | 0.21 (0.14 to 0.32) | 1.11 (0.79 to 1.57) | 3.16 (1.87 to 5.34) |
| Anti-PSY, Month 12 | 2.36 (1.75 to 3.18) | 0.21 (0.14 to 0.33) | 1.84 (1.2 to 2.82) | 6.9 (4.51 to 10.54) |
A seropositive subject for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY was defined as a vaccinated subject with antibody titers greater than or equal to (≥) 1:128, while for a seroprotected subject, titers were ≥1:8.
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group |
|---|---|---|
| rSBA-MenA ≥ 1:8, PRE | 20 | 17 |
| rSBA-MenC ≥ 1:8, PRE | 25 | 20 |
| rSBA-MenW-135 ≥ 1:8, PRE | 26 | 9 |
| rSBA-MenY ≥ 1:8, PRE | 27 | 18 |
| rSBA-MenA ≥ 1:128, PRE | 20 | 16 |
| rSBA-MenC ≥ 1:128, PRE | 10 | 12 |
| rSBA-MenW-135 ≥ 1:128, PRE | 23 | 4 |
| rSBA-MenY ≥ 1:128, PRE | 26 | 14 |
| rSBA-MenA ≥ 1:8, Month 13 | 6 | 19 |
| rSBA-MenC ≥ 1:8, Month 13 | 25 | 24 |
| rSBA-MenW-135 ≥ 1:8, Month 13 | 25 | 21 |
| rSBA-MenY ≥ 1:8, Month 13 | 25 | 22 |
| rSBA-MenA ≥ 1:128, Month 13 | 6 | 19 |
| rSBA-MenC ≥ 1:128, Month 13 | 24 | 24 |
| rSBA-MenW-135 ≥ 1:128, Month 13 | 25 | 18 |
| rSBA-MenY ≥ 1:128, Month 13 | 25 | 20 |
Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs).
| Titers | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group |
|---|---|---|
| rSBA-MenA, PRE | 2163.4 (1436.6 to 3257.9) | 175.7 (70.5 to 437.8) |
| rSBA-MenC, PRE | 82.5 (50.3 to 135.4) | 102.5 (47.7 to 220.3) |
| rSBA-MenW-135, PRE | 436 (243.7 to 780.2) | 15.5 (7 to 34.3) |
| rSBA-MenY, PRE | 634.5 (420 to 958.3) | 93.6 (38.4 to 228.1) |
| rSBA-MenA, Month 13 | 3695.2 (1535.2 to 8894.7) | 984.6 (479.7 to 2021.2) |
| rSBA-MenC, Month 13 | 7067.4 (4070.7 to 12270.3) | 9209.3 (5153.4 to 16457.5) |
| rSBA-MenW-135, Month 13 | 5642.4 (3360 to 9475.4) | 255.6 (110.1 to 593.6) |
| rSBA-MenY, Month 13 | 3337.7 (2013.7 to 5532.1) | 323.8 (153.6 to 682.7) |
A seropositive subject for anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY was defined as a vaccinated subject with antibody concentrations greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL), while for a seroprotected subject, antibody concentrations were ≥ 2.0 μg/mL.
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group |
|---|---|---|
| Anti-PSA ≥ 0.3 μg/mL, PRE | 19 | 1 |
| Anti-PSC ≥ 0.3 μg/mL, PRE | 11 | 15 |
| Anti-PSW-135 ≥ 0.3 μg/mL, PRE | 23 | 2 |
| Anti-PSY ≥ 0.3 μg/mL, PRE | 24 | 2 |
| Anti-PSA ≥ 2.0 μg/mL, PRE | 7 | 0 |
| Anti-PSC ≥ 2.0 μg/mL, PRE | 1 | 3 |
| Anti-PSW-135 ≥ 2.0 μg/mL, PRE | 5 | 1 |
| Anti-PSY ≥ 2.0 μg/mL, PRE | 14 | 0 |
| Anti-PSA ≥ 0.3 μg/mL, Month 13 | 26 | 19 |
| Anti-PSC ≥ 0.3 μg/mL, Month 13 | 25 | 22 |
| Anti-PSW-135 ≥ 0.3 μg/mL, Month 13 | 25 | 18 |
| Anti-PSY ≥ 0.3 μg/mL, Month 13 | 25 | 20 |
| Anti-PSA ≥ 2.0 μg/mL, Month 13 | 25 | 13 |
| Anti-PSC ≥ 2.0 μg/mL, Month 13 | 25 | 22 |
| Anti-PSW-135 ≥ 2.0 μg/mL, Month 13 | 24 | 9 |
| Anti-PSY ≥ 2.0 μg/mL, Month 13 | 24 | 12 |
The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).
| μg/mL | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group |
|---|---|---|
| Anti-PSA, PRE | 0.98 (0.56 to 1.69) | 0.16 (0.14 to 0.18) |
| Anti-PSC, PRE | 1.33 (1.02 to 1.72) | 0.19 (0.13 to 0.27) |
| Anti-PSW-135, PRE | 25.67 (17.39 to 37.91) | 3.1 (1.34 to 7.2) |
| Anti-PSY, PRE | 56.94 (35.87 to 90.38) | 1.34 (0.63 to 2.88) |
| Anti-PSA, Month 13 | 0.32 (0.22 to 0.48) | 0.5 (0.31 to 0.8) |
| Anti-PSC, Month 13 | 2.34 (1.69 to 3.24) | 0.19 (0.13 to 0.26) |
| Anti-PSW-135, Month 13 | 11.63 (7.73 to 17.5) | 15.23 (10.66 to 21.77) |
| Anti-PSY, Month 13 | 79.03 (52.06 to 119.97) | 4.19 (2 to 8.78) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group |
|---|---|---|
| Any Pain | 1 | 0 |
| Any Redness | 3 | 3 |
| Any Swelling | 1 | 1 |
Assessed solicited general symptoms were drowsiness, fever \[defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)\], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination.
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group |
|---|---|---|
| Any Drowsiness | 3 | 5 |
| Any Fever (Rectally) | 5 | 3 |
| Any Irritability | 4 | 5 |
| Any Loss of appetite | 2 | 2 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination | 11 | 16 | 5 | 8 | 14 | 6 | 12 | 7 | 5 | 6 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group |
|---|---|---|---|---|---|
| Number of Subjects With Any Unsolicited AEs During the Primary Vaccination | 5 | 8 | 5 | 5 | 7 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group |
|---|---|---|
| Number of Subjects With Any Unsolicited AEs | 3 | 5 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|
| Number of Subjects With SAEs | 0 | 0 | 0 | 0 |
Collected over Solicited symptoms: during the 8-day (Days 0-7) post-vaccination period. Unsolicited AEs: within 31 days (Days 0-30) after each vaccination. SAEs: from the beginning of the primary study up to the end of the booster study (from Month 0 up to Month 13).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK134612A Form1 (T), Primary Group | 0/39 (0%) | 1/39 (2.6%) | 20/39 (51.3%) |
| GSK134612A Form2 (T), Primary Group | 0/41 (0%) | 1/41 (2.4%) | 27/41 (65.9%) |
| GSK134612A Form3 (T), Primary Group | 0/41 (0%) | 1/41 (2.4%) | 23/41 (56.1%) |
| GSK134612A Form4 (T), Primary Group | 0/40 (0%) | 1/40 (2.5%) | 24/40 (60%) |
| Control (T), Primary Group | 0/40 (0%) | 1/40 (2.5%) | 25/40 (62.5%) |
| GSK134612A Form1 (C), Primary Group | 0/54 (0%) | 0/54 (0%) | 10/54 (18.5%) |
| GSK134612A Form2 (C), Primary Group | 0/50 (0%) | 0/50 (0%) | 11/50 (22%) |
| GSK134612A Form3 (C), Primary Group | 0/52 (0%) | 0/52 (0%) | 10/52 (19.2%) |
| GSK134612A Form4 (C), Primary Group | 0/52 (0%) | 0/52 (0%) | 11/52 (21.2%) |
| Control (C), Primary Group | 0/52 (0%) | 0/52 (0%) | 13/52 (25%) |
| GSK134612A Form1 (T), Booster Group | 0/33 (0%) | 0/33 (0%) | 5/33 (15.2%) |
| Control (T), Booster Group | 0/32 (0%) | 0/32 (0%) | 5/32 (15.6%) |
| GSK134612A Form1 (C), Booster Group | 0/45 (0%) | 0/45 (0%) | — |
| Control (C), Booster Group | 0/43 (0%) | 0/43 (0%) | — |
| Event | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bronchiolitis (toddlers subgroup)Infections and infestations | 1/39 | 0/41 | 0/41 | 0/40 | 0/40 | 0/54 | 0/50 | 0/52 | 0/52 | 0/52 | 0/33 | 0/32 | 0/45 | 0/43 |
| Maculo-papular rash (toddlers subgroup)Skin and subcutaneous tissue disorders | 0/39 | 0/41 | 0/41 | 0/40 | 1/40 | 0/54 | 0/50 | 0/52 | 0/52 | 0/52 | 0/33 | 0/32 | 0/45 | 0/43 |
| Laryngitis (toddlers subgroup)Infections and infestations | 0/39 | 0/41 | 1/41 | 1/40 | 0/40 | 0/54 | 0/50 | 0/52 | 0/52 | 0/52 | 0/33 | 0/32 | 0/45 | 0/43 |
| Acute bronchitis (toddlers subgroup)Infections and infestations | 0/39 | 1/41 | 0/41 | 0/40 | 0/40 | 0/54 | 0/50 | 0/52 | 0/52 | 0/52 | 0/33 | 0/32 | 0/45 | 0/43 |
| Event | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redness (Infanrix™-containing vaccine)General disorders | 7/38 | 13/39 | 9/37 | 8/39 | 7/37 | — | — | — | — | — | — | — | — | — |
| Redness (GSK134612A conjugate vaccine)General disorders | 9/38 | 12/41 | 10/39 | 9/40 | 11/39 | 9/52 | 11/50 | 10/50 | 9/52 | 7/51 | 3/31 | 3/30 | — | — |
| Pain (Infanrix™-containing vaccine)General disorders | 3/38 | 10/39 | 6/37 | 7/39 | 6/37 | — | — | — | — | — | — | — | — | — |
| Pain (GSK134612A conjugate vaccine)General disorders | 4/38 | 8/41 | 3/39 | 6/40 | 4/39 | 10/52 | 11/50 | 9/50 | 11/52 | 13/51 | 1/31 | 0/30 | — | — |
| Swelling (Infanrix™-containing vaccine)General disorders | 3/38 | 7/39 | 9/37 | 7/39 | 3/37 | — | — | — | — | — | — | — | — | — |
| Irritability (Infanrix™-containing vaccine)General disorders | 6/38 | 7/39 | 3/37 | 9/39 | 5/37 | — | — | — | — | — | — | — | — | — |
| Irritability (GSK134612A conjugate vaccine)General disorders | 4/38 | 9/41 | 6/39 | 5/40 | 5/39 | 2/52 | 4/50 | 2/50 | 4/52 | 7/51 | 4/31 | 5/30 | — | — |
| Axillary fever (Infanrix™-containing vaccine)General disorders | 4/38 | 5/39 | 5/37 | 5/39 | 8/37 | — | — | — | — | — | — | — | — | — |
| Axillary/Rectally fever (GSK134612A conjugate vaccine)General disorders | 5/38 | 8/41 | 8/39 | 3/40 | 5/39 | 4/52 | 4/50 | 3/50 | 3/52 | 3/51 | 5/31 | 3/30 | — | — |
| Swelling (GSK134612A conjugate vaccine)General disorders | 1/38 | 6/41 | 7/39 | 6/40 | 4/39 | 7/52 | 9/50 | 8/50 | 10/52 | 4/51 | 1/31 | 1/30 | — | — |
| Age, Continuous(Months) | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 12.5 ± 0.82 | 12.8 ± 0.86 | 12.8 ± 0.86 | 12.9 ± 0.83 | 12.8 ± 0.79 | 48.1 ± 7.12 | 48 ± 7.22 | 47.8 ± 7.01 | 48 ± 7.78 | 47.7 ± 7.15 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 32.59 ± 4.45 |
| Age, Continuous(Months) | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 24.9 ± 1.24 | 24.9 ± 1.27 | 60.8 ± 7.23 | 60.0 ± 7.36 | 45.32 ± 18.47 |
| Sex: Female, Male(Participants) | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 15 | 15 | 17 | 24 | 19 | 21 | 16 | 23 | 27 | 27 | NA | NA | NA | NA | NA |
| Male | 24 | 26 | 24 | 16 | 21 | 33 | 34 | 29 | 25 | 25 | NA | NA | NA | NA | NA |
| Sex: Female, Male(Participants) | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 11 | 15 | 16 | 23 | NA |
| Male | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 22 | 17 | 29 | 20 | NA |
| Race/Ethnicity, Customized(Participants) | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White/ Caucasian | 38 | 40 | 40 | 38 | 39 | 53 | 50 | 50 | 50 | 51 | NA | NA | NA | NA | NA |
| Arabic/ north african | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 2 | 1 | 0 | NA | NA | NA | NA | NA |
| East/ south east asian | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NA | NA | NA | NA |
| Black | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | NA | NA | NA | NA | NA |
| Race/Ethnicity, Customized(Participants) | GSK134612A Form1 (T), Primary Group | GSK134612A Form2 (T), Primary Group | GSK134612A Form3 (T), Primary Group | GSK134612A Form4 (T), Primary Group | Control (T), Primary Group | GSK134612A Form1 (C), Primary Group | GSK134612A Form2 (C), Primary Group | GSK134612A Form3 (C), Primary Group | GSK134612A Form4 (C), Primary Group | Control (C), Primary Group | GSK134612A Form1 (T), Booster Group | Control (T), Booster Group | GSK134612A Form1 (C), Booster Group | Control (C), Booster Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White/Caucasian | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 32 | 31 | 44 | 43 | NA |
| Arabic/north African | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1 | 1 | 1 | 0 | NA |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Mar 2005, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 11 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine